Back to Results

Emergent Biosolutions Inc (EBS)

Emergent BioSolutions Inc. is a healthcare company focused on preparedness and response solutions for public health threats that are accidental, deliberate, or naturally occurring. The company operates in the United States, Canada, and international markets, and reports results through Commercial Products, MCM Products, and All Other Revenues segments. Its portfolio includes vaccines and therapeutics for threats such as smallpox, mpox, anthrax, botulism, Ebola, and opioid overdose, including ACAM2000, BioThrax, CYFENDUS, Ebanga, TEMBEXA, NARCAN, and KLOXXADO. Emergent also provides contract development and manufacturing services, including drug substance and product manufacturing, packaging, and related development and transfer services. Incorporated in 1998, the company is headquartered in Gaithersburg, Maryland.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-EBS
$7.04
13.0% Upside
Fair
$11
76.6% Upside
Bargain
Good
0.0%
0.9x
0.4x
319.4 M
767.9 M
64.8%
95.7%
1.9
-48.6%
Valuation • Fair Value

Emergent Biosolutions Inc (NYSE-EBS) Fair Value by Valuation Model

Review the available estimates for Emergent Biosolutions Inc (NYSE-EBS), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$7.04

Estimated upside of 13.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$12.03

Discounted cash flow valuation reference.

Comps Fair Value

$6.21

Comparable-company valuation reference.

Analyst Price Target

$11

Analysts imply upside of 76.6%.

How to read these valuation models

Use the 5 available valuation references for Emergent Biosolutions Inc (NYSE-EBS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Emergent Biosolutions Inc (NYSE-EBS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

770.2 M

Current operating scale indicator.

Revenue Forecast

660 M

Forward revenue estimate.

EBITDA

234.9 M

Current operating profitability reference.

EBITDA Forecast

133.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Emergent Biosolutions Inc (NYSE-EBS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Emergent Biosolutions Inc (NYSE-EBS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.37

No elevated caution signal from this screen.

Altman Z-Score

1.9

Intermediate risk zone.

FCF / Net Income

-48.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Emergent Biosolutions Inc (NYSE-EBS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Emergent Biosolutions Inc (NYSE-EBS)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Emergent Biosolutions Inc (NYSE-EBS). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Emergent Biosolutions Inc (NYSE-EBS) Stock Forecast & Technical Outlook

Review Emergent Biosolutions Inc (NYSE-EBS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Emergent Biosolutions Inc (NYSE-EBS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Emergent Biosolutions Inc (NYSE-EBS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Emergent Biosolutions Inc (NYSE-EBS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Emergent Biosolutions Inc (NYSE-EBS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Emergent Biosolutions Inc (NYSE-EBS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Emergent Biosolutions Inc (NYSE-EBS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Emergent Biosolutions Inc (NYSE-EBS) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Emergent Biosolutions Inc (NYSE-EBS) Stock FAQ

Data-supported answers about Emergent Biosolutions Inc (NYSE-EBS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$7.04
Estimated upside 13.0%
Valuation Rating
Undervalued
Estimated upside of 13.0%
Analyst Target
$11
Implied upside 76.6%
Financial Health
Good
Current financial-health read

The current fair value estimate for Emergent Biosolutions Inc (NYSE-EBS) is $7.04. This implies an estimated upside of 13.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 13.0% versus the current market price.

The available analyst price target for Emergent Biosolutions Inc (NYSE-EBS) is $11. The analyst target implies estimated upside of 76.6%.

The current financial health read for Emergent Biosolutions Inc (NYSE-EBS) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Emergent Biosolutions Inc (NYSE-EBS).

The current market capitalization listed for Emergent Biosolutions Inc is 319.4 M.

The current enterprise value listed for Emergent Biosolutions Inc is 767.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Emergent Biosolutions Inc is NYSE-EBS, and the stock is listed on NYSE.

Emergent Biosolutions Inc (NYSE-EBS) is listed on NYSE.

The current debt-to-total-capital ratio listed for Emergent Biosolutions Inc is 64.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Emergent Biosolutions Inc is 95.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 504.8 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 237.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 193.5 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 132.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.385 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 79.887 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 58.227 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 54.76 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 42.937 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Overvalued Market Cap 40.079 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 37.04 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 29.977 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.358 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 25.198 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 23.663 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 23.454 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 22.135 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 20.395 B
EXEL NASDAQ Exelixis Inc Fair Value Overvalued Market Cap 15.989 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.983 B